AstraZeneca has confirmed that it is maintaining a pause on its planned expansion of a major research facility in Cambridge, while leaving open the possibility of reviving the project at a later stage.

The company said the decision reflects an ongoing review of the United Kingdom’s life sciences environment, including regulatory and commercial conditions that influence long-term investment planning.

The proposed expansion, valued at around two hundred million pounds, was intended to add new laboratory, office and conference space at the Cambridge Biomedical Campus and support significant job creation.

Although recent planning submissions for additional buildings prompted speculation that the project was being restarted, AstraZeneca clarified that these steps were taken to preserve flexibility rather than signal an immediate resumption of construction.

The pause follows wider concerns within the pharmaceutical sector about the attractiveness of the UK as a destination for large-scale research investment.

Industry leaders have pointed to uncertainty surrounding medicines pricing, reimbursement frameworks and government incentives as factors weighing on long-term commitments.

AstraZeneca has previously scaled back or cancelled other UK-based projects, while continuing to expand research and manufacturing capacity in other global markets.

Despite the delay, the company emphasised that it remains committed to its existing UK operations and continues to view Cambridge as a strategically important research hub.

Executives indicated that the expansion could still proceed if conditions become more supportive, underscoring that the project has not been abandoned but remains under active consideration as part of AstraZeneca’s global investment strategy.